Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MC4R | P32245 | 1/20 | 0.35 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4545011 | 0.90 | ACHE (0.40) | BCHEACHEALDH1A1L3MBTL1MC4R | |
| SCHEMBL12018213 | 0.88 | BCHE (0.45) | BCHEACHEALDH1A1L3MBTL1MAPT | |
| SCHEMBL4545009 | 0.86 | CYP2D6 (0.36) | BCHEACHEALDH1A1MC4RKCNA5 | |
| SCHEMBL10245022 | 0.82 | CA1 (0.44) | ACHEALDH1A1L3MBTL1MC4RHTT | |
| SCHEMBL11886646 | 0.82 | CA1 (0.44) | ACHEALDH1A1L3MBTL1MC4RHTT | |
| SCHEMBL1132754 | 0.80 | TAAR1 (0.41) | ACHEALDH1A1L3MBTL1MC4RHTT | |
| SCHEMBL12608137 | 0.80 | ALDH1A1 (0.48) | BCHEACHEALDH1A1MC4RCA2 | |
| SCHEMBL334589 | 0.80 | MC4R (0.38) | BCHEACHEALDH1A1L3MBTL1MC4R | |
| SCHEMBL334590 | 0.80 | MC4R (0.38) | BCHEACHEALDH1A1L3MBTL1MC4R | |
| SCHEMBL334999 | 0.80 | TAAR1 (0.41) | ACHEALDH1A1L3MBTL1MC4RHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120216867-A1 | FULLERENE DERIVATIVES | NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY (JP) | 2012-08-30 | — | — | US | disclosed |
| US-20120111411-A1 | FULLERENE DERIVATIVE | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120111411-A1 | FULLERENE DERIVATIVE | HCN2, KCNN2, TMEM109 | BCHE 4202/4885ACHE 2879/4885ALDH1A1 1309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.